{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:28:48Z","timestamp":1776857328309,"version":"3.51.2"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/pcan.2016.69","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T12:00:16Z","timestamp":1485259216000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update"],"prefix":"10.1038","volume":"20","author":[{"given":"P J","family":"Owen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S F","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"BFpcan201669_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201669_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61\u201371.","journal-title":"Eur Urol"},{"key":"BFpcan201669_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.acuro.2011.03.011","volume":"35","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol Esp 2011; 35: 565\u2013579.","journal-title":"Actas Urol Esp"},{"key":"BFpcan201669_CR4","doi-asserted-by":"publisher","first-page":"R305","DOI":"10.1677\/ERC-10-0187","volume":"17","author":"N Sharifi","year":"2010","unstructured":"Sharifi N, Gulley JL, Dahut WL . An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010; 17: R305\u2013R315.","journal-title":"Endocr Relat Cancer"},{"key":"BFpcan201669_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","volume":"360","author":"M Bolla","year":"2002","unstructured":"Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised rial. Lancet 2002; 360: 103\u2013108.","journal-title":"Lancet"},{"key":"BFpcan201669_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841\u2013850.","journal-title":"Lancet Oncol"},{"key":"BFpcan201669_CR7","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/S0022-5347(01)63235-X","volume":"159","author":"T Granfors","year":"1998","unstructured":"Granfors T, Modig H, Damber J-E, Tomic R . Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998; 159: 2030\u20132034.","journal-title":"J Urol"},{"key":"BFpcan201669_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472\u2013479.","journal-title":"Lancet Oncol"},{"key":"BFpcan201669_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","volume":"61","author":"MV Pilepich","year":"2005","unstructured":"Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85\u201331. Int J Radiat Oncol Biol Phys 2005; 61: 1285\u20131290.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFpcan201669_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.292.7.821","volume":"292","author":"AV D'Amico","year":"2004","unstructured":"D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW . 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821\u2013827.","journal-title":"JAMA"},{"key":"BFpcan201669_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jama.300.2.173","volume":"300","author":"GL Lu-Yao","year":"2008","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola R et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173\u2013181.","journal-title":"JAMA"},{"key":"BFpcan201669_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamainternmed.2014.3028","volume":"174","author":"GL Lu-Yao","year":"2014","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer. JAMA Intern Med 2014; 174: 1460\u20131467.","journal-title":"JAMA Intern Med"},{"key":"BFpcan201669_CR13","doi-asserted-by":"publisher","first-page":"e000040","DOI":"10.1136\/esmoopen-2016-000040","volume":"1","author":"A Liede","year":"2016","unstructured":"Liede A, Hallett DC, Hope K, Graham A, Arellano J, Shahinian VB . International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open 2016; 1: e000040.","journal-title":"ESMO Open"},{"key":"BFpcan201669_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/00365590310018810","volume":"38","author":"I Bergstr\u00f6m","year":"2004","unstructured":"Bergstr\u00f6m I, Gustafsson H, Sj\u00f6berg K, Arver S . Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer: a prospective, controlled, parallel-groupstudy. Scand J Urol Nephrol 2004; 38: 148\u2013152.","journal-title":"Scand J Urol Nephrol"},{"key":"BFpcan201669_CR15","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"A Berruti","year":"2002","unstructured":"Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361\u20132367.","journal-title":"J Urol"},{"key":"BFpcan201669_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT . Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181\u2013186.","journal-title":"J Urol"},{"key":"BFpcan201669_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galv\u00e3o","year":"2008","unstructured":"Galv\u00e3o DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44\u201347.","journal-title":"BJU Int"},{"key":"BFpcan201669_CR18","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410\u20136417.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.urology.2004.07.019","volume":"64","author":"C Higano","year":"2004","unstructured":"Higano C, Shields A, Wood N, Brown J, Tangen C . Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 1182\u20131186.","journal-title":"Urology"},{"key":"BFpcan201669_CR20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/cncr.21381","volume":"104","author":"H Lee","year":"2005","unstructured":"Lee H, McGovern K, Finkelstein JS, Smith MR . Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633\u20131637.","journal-title":"Cancer"},{"key":"BFpcan201669_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"JF Maillefert","year":"1999","unstructured":"Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C . Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219\u20131222.","journal-title":"J Urol"},{"key":"BFpcan201669_CR22","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM . Bone loss following hypogonadism in men with prostate cancer treated with GNRH analogs. J Clin Endocrinol Metab 2002; 87: 3656\u20133661.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR23","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","volume":"175","author":"J Morote","year":"2006","unstructured":"Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006; 175: 1679\u20131683.","journal-title":"J Urol"},{"key":"BFpcan201669_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","volume":"5","author":"DM Preston","year":"2002","unstructured":"Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, McLeod DG . Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002; 5: 304.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201669_CR25","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546\u20132553.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","volume":"63","author":"MR Smith","year":"2004","unstructured":"Smith MR . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742\u2013745.","journal-title":"Urology"},{"key":"BFpcan201669_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR28","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostatecancer. Cancer 2008; 112: 2188\u20132194.","journal-title":"Cancer"},{"key":"BFpcan201669_CR29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305\u20131308.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR30","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261\u20134267.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/13685530500361226","volume":"8","author":"RS Boxer","year":"2005","unstructured":"Boxer RS, Kenny AM, Dowsett R, Taxel P . The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 2005; 8: 207\u2013212.","journal-title":"Aging Male"},{"key":"BFpcan201669_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/pcan.2012.33","volume":"16","author":"NA Spry","year":"2013","unstructured":"Spry NA, Taaffe DR, England PJ, Judge JS, Stephens DA, Peddle-McIntyre C et al. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study. Prostate Cancer Prostatic Dis 2013; 16: 67\u201372.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201669_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.urology.2008.03.032","volume":"72","author":"K Bylow","year":"2008","unstructured":"Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 2008; 72: 422\u2013427.","journal-title":"Urology"},{"key":"BFpcan201669_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","volume":"184","author":"SMH Alibhai","year":"2010","unstructured":"Alibhai SMH, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010; 184: 918\u2013924.","journal-title":"J Urol"},{"key":"BFpcan201669_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154\u2013164.","journal-title":"N Engl J Med"},{"key":"BFpcan201669_CR36","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL . Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897\u20137903.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11606-009-0968-y","volume":"24","author":"P Saylor","year":"2009","unstructured":"Saylor P, Keating N, Smith M . Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24: 389\u2013394.","journal-title":"J Gen Intern Med"},{"key":"BFpcan201669_CR38","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL . Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115: 2388\u20132399.","journal-title":"Cancer"},{"key":"BFpcan201669_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/pon.3608","volume":"24","author":"M Lee","year":"2015","unstructured":"Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M et al. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psychooncology 2015; 24: 472\u2013477.","journal-title":"Psychooncology"},{"key":"BFpcan201669_CR40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","volume":"194","author":"M Grossmann","year":"2011","unstructured":"Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD . Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 2011; 194: 301\u2013306.","journal-title":"Med J Aust"},{"key":"BFpcan201669_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/aja.2011.108","volume":"14","author":"RG Casey","year":"2012","unstructured":"Casey RG, Corcoran NM, Goldenberg SL . Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl 2012; 14: 226\u2013231.","journal-title":"Asian J Androl"},{"key":"BFpcan201669_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1359\/jbmr.2000.15.4.710","volume":"15","author":"MT Hannan","year":"2000","unstructured":"Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PWF et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 710\u2013720.","journal-title":"J Bone Miner Res"},{"key":"BFpcan201669_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-010-1330-2","volume":"22","author":"Y Sheu","year":"2011","unstructured":"Sheu Y, Cauley JA, Wheeler VW, Patrick AL, Bunker CH, Ensrud KE et al. Age-related decline in bone density among ethnically diverse older men. Osteoporosis Int 2011; 22: 599\u2013605.","journal-title":"Osteoporosis Int"},{"key":"BFpcan201669_CR44","doi-asserted-by":"publisher","first-page":"E456","DOI":"10.1210\/jc.2010-0902","volume":"95","author":"EJ Hamilton","year":"2010","unstructured":"Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010; 95: E456\u2013E463.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR45","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","volume":"83","author":"T Diamond","year":"1998","unstructured":"Diamond T, Campbell J, Bryant C, Lynch W . The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561\u20131566.","journal-title":"Cancer"},{"key":"BFpcan201669_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.2258","volume":"21","author":"JL Beebe-Dimmer","year":"2012","unstructured":"Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL et al. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol Drug Saf 2012; 21: 70\u201378.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"BFpcan201669_CR47","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00198-015-3135-9","volume":"26","author":"C-T Wu","year":"2015","unstructured":"Wu C-T, Yang Y-H, Chen P-C, Chen M-F, Chen W-C . Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporosis Int 2015; 26: 2281\u20132290.","journal-title":"Osteoporosis Int"},{"key":"BFpcan201669_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.radonc.2009.08.004","volume":"93","author":"C Fiorino","year":"2009","unstructured":"Fiorino C, Valdagni R, Rancati T, Sanguineti G . Dose\u2013volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009; 93: 153\u2013167.","journal-title":"Radiother Oncol"},{"key":"BFpcan201669_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-015-0536-7","volume":"50","author":"AC Lassemillante","year":"2015","unstructured":"Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR . Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocrine 2015; 50: 344\u2013354.","journal-title":"Endocrine"},{"key":"BFpcan201669_CR50","doi-asserted-by":"publisher","first-page":"B209","DOI":"10.1093\/gerona\/56.5.B209","volume":"56","author":"VA Hughes","year":"2001","unstructured":"Hughes VA, Frontera WR, Wood M, Evans WJ, Dallal GE, Roubenoff R et al. Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci 2001; 56: B209\u2013B217.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BFpcan201669_CR51","doi-asserted-by":"publisher","first-page":"B198","DOI":"10.1093\/gerona\/56.5.B198","volume":"56","author":"ME Sehl","year":"2001","unstructured":"Sehl ME, Yates FE . Kinetics of human aging: I. rates of senescence between ages 30 and 70 years in healthy people. J Gerontol A Biol Sci Med Sci 2001; 56: B198\u2013B208.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BFpcan201669_CR52","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 2012; 30: 3271\u20133276.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.mad.2004.01.004","volume":"125","author":"S Mudali","year":"2004","unstructured":"Mudali S, Dobs AS . Effects of testosterone on body composition of the aging male. Mech Ageing Dev 2004; 125: 297\u2013304.","journal-title":"Mech Ageing Dev"},{"key":"BFpcan201669_CR54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/aja.2011.104","volume":"14","author":"TW Storer","year":"2012","unstructured":"Storer TW, Miciek R, Travison TG . Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl 2012; 14: 204\u2013221.","journal-title":"Asian J Androl"},{"key":"BFpcan201669_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","volume":"74","author":"EJ Hamilton","year":"2011","unstructured":"Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 2011; 74: 377\u2013383.","journal-title":"Clin Endocrinol"},{"key":"BFpcan201669_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1754-9485.12124","volume":"58","author":"D Chang","year":"2014","unstructured":"Chang D, Joseph DJ, Ebert MA, Galv\u00e3o DA, Taaffe DR, Denham JW et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostatecancer. J Med Imaging Radiat Oncol 2014; 58: 223\u2013228.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"BFpcan201669_CR57","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979\u20133983.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR58","doi-asserted-by":"publisher","first-page":"309570","DOI":"10.1155\/2014\/309570","volume":"2014","author":"O Addison","year":"2014","unstructured":"Addison O, Marcus RL, Lastayo PC, Ryan AS . Intermuscular fat: a review of the consequences and causes. Int J Endocrinol 2014; 2014: 309570.","journal-title":"Int J Endocrinol"},{"key":"BFpcan201669_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2014.12.023","volume":"96A","author":"A Aguilar-Valles","year":"2015","unstructured":"Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN . Obesity, adipokines and neuroinflammation. Neuropharmacology 2015; 96A: 124\u2013134.","journal-title":"Neuropharmacology"},{"key":"BFpcan201669_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","volume":"22","author":"JM Argil\u00e9s","year":"2015","unstructured":"Argil\u00e9s JM, Busquets S, Stemmler B, L\u00f3pez-Soriano FJ . Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol 2015; 22: 100\u2013106.","journal-title":"Curr Opin Pharmacol"},{"key":"BFpcan201669_CR61","doi-asserted-by":"publisher","first-page":"f7524","DOI":"10.1136\/bmj.f7524","volume":"348","author":"J Graham","year":"2014","unstructured":"Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M . Prostate cancer: summary of updated NICE guidance. BMJ 2014; 348: f7524.","journal-title":"BMJ"},{"key":"BFpcan201669_CR62","doi-asserted-by":"publisher","first-page":"E163","DOI":"10.3747\/co.v18i4.746","volume":"18","author":"CE Lee","year":"2011","unstructured":"Lee CE, Leslie WD, Czaykowski P, Gingerich J, Geirnaert M, Lau YKJ . A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol 2011; 18: E163\u2013E172.","journal-title":"Curr Oncol"},{"key":"BFpcan201669_CR63","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67: 825\u2013836.","journal-title":"Eur Urol"},{"key":"BFpcan201669_CR64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.2047-2927.2013.00093.x","volume":"1","author":"AS Cheung","year":"2013","unstructured":"Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology 2013; 1: 583\u2013589.","journal-title":"Andrology"},{"key":"BFpcan201669_CR65","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-152-10-201005180-00002","volume":"152","author":"K Ito","year":"2010","unstructured":"Ito K, Elkin EB, Girotra M, Morris MJ . Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152: 621\u2013629.","journal-title":"Ann Intern Med"},{"key":"BFpcan201669_CR66","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.27830","volume":"119","author":"AK Morgans","year":"2013","unstructured":"Morgans AK, Smith MR, O'Malley AJ, Keating NL . Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer 2013; 119: 863\u2013870.","journal-title":"Cancer"},{"key":"BFpcan201669_CR67","doi-asserted-by":"publisher","first-page":"686","DOI":"10.5694\/mja11.10301","volume":"196","author":"CA Nowson","year":"2012","unstructured":"Nowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust 2012; 196: 686\u2013687.","journal-title":"Med J Aust"},{"key":"BFpcan201669_CR68","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1634\/theoncologist.2012-0051","volume":"17","author":"M Datta","year":"2012","unstructured":"Datta M, Schwartz GG . Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 2012; 17: 1171\u20131179.","journal-title":"Oncologist"},{"key":"BFpcan201669_CR69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3945\/ajcn.113.067157","volume":"100","author":"D Aune","year":"2015","unstructured":"Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr 2015; 100: 87\u2013117.","journal-title":"Am J Clin Nutr"},{"key":"BFpcan201669_CR70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1210\/jc.2007-1402","volume":"93","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL . Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008; 93: 2\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201669_CR71","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1210\/jc.2012-1451","volume":"97","author":"DT Marshall","year":"2012","unstructured":"Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocr Metab 2012; 97: 2315\u20132324.","journal-title":"J Clin Endocr Metab"},{"key":"BFpcan201669_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2490-10-9","volume":"10","author":"A Serpa Neto","year":"2010","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves M, Senra M, Wroclawski M, Fonseca F et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 2010; 10: 9.","journal-title":"BMC Urol"},{"key":"BFpcan201669_CR73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MAP, Senra MD, Wroclawski ML, Fonseca FLA et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36\u201344.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201669_CR74","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1200\/JCO.2013.49.5523","volume":"32","author":"JR Gardner","year":"2014","unstructured":"Gardner JR, Livingston PM, Fraser SF . Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 2014; 32: 335\u2013346.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR75","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","volume":"38","author":"DA Galv\u00e3o","year":"2006","unstructured":"Galv\u00e3o DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sport Exerc 2006; 38: 2045\u20132052.","journal-title":"Med Sci Sport Exerc"},{"key":"BFpcan201669_CR76","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1249\/MSS.0000000000000265","volume":"46","author":"KM Winters-Stone","year":"2014","unstructured":"Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer TM . Skeletal response to resistance and impact training in prostate cancer survivors. Med Sci Sports Exerc 2014; 46: 1482\u20131488.","journal-title":"Med Sci Sports Exerc"},{"key":"BFpcan201669_CR77","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bju.12646","volume":"115","author":"P Cormie","year":"2015","unstructured":"Cormie P, Galv\u00e3o DA, Spry N, Joseph D, Chee R, Taaffe DR et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 2015; 115: 256\u2013266.","journal-title":"BJU Int"},{"key":"BFpcan201669_CR78","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3109\/0284186X.2015.1037008","volume":"54","author":"TS Nilsen","year":"2015","unstructured":"Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol 2015; 54: 1805\u20131813.","journal-title":"Acta Oncol"},{"key":"BFpcan201669_CR79","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00198-008-0776-y","volume":"20","author":"S Kukuljan","year":"2009","unstructured":"Kukuljan S, Nowson CA, Bass SL, Sanders K, Nicholson GC, Seibel MJ et al. Effects of a multi-component exercise program and calcium-vitamin-D3-fortified milk on bone mineral density in older men: a randomised controlled trial. Osteoporosis Int 2009; 20: 1241\u20131251.","journal-title":"Osteoporosis Int"},{"key":"BFpcan201669_CR80","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s11357-011-9311-8","volume":"34","author":"E Marques","year":"2012","unstructured":"Marques E, Mota J, Carvalho J . Exercise effects on bone mineral density in older adults: a meta-analysis of randomized controlled trials. Age 2012; 34: 1493\u20131515.","journal-title":"Age"},{"key":"BFpcan201669_CR81","unstructured":"American College of Sports Medicine ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription, 6th edn. Lippincott Williams & Wilkins: Philadelphia, USA, 2010."},{"key":"BFpcan201669_CR82","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/02640414.2012.671953","volume":"30","author":"A Campbell","year":"2012","unstructured":"Campbell A, Stevinson C, Crank H . The BASES expert statement on exercise and cancer survivorship. J Sport Sci 2012; 30: 949\u2013952.","journal-title":"J Sport Sci"},{"key":"BFpcan201669_CR83","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jsams.2009.03.002","volume":"12","author":"SC Hayes","year":"2009","unstructured":"Hayes SC, Spence RR, Galv\u00e3o DA, Newton RU . Australian association for exercise and sport science position stand: optimising cancer outcomes through exercise. J Sci Med Sport 2009; 12: 428\u2013434.","journal-title":"J Sci Med Sport"},{"key":"BFpcan201669_CR84","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3322\/caac.21142","volume":"62","author":"CL Rock","year":"2012","unstructured":"Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 242\u2013274.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201669_CR85","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","volume":"42","author":"KH Schmitz","year":"2010","unstructured":"Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galv\u00e3o DA, Pinto BM et al. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sport Exerc 2010; 42: 1409\u20131426.","journal-title":"Med Sci Sport Exerc"},{"key":"BFpcan201669_CR86","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00520-011-1169-x","volume":"20","author":"A Alberga","year":"2012","unstructured":"Alberga A, Segal R, Reid R, Scott C, Sigal R, Khandwala F et al. Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer. Support Care Cancer 2012; 20: 971\u2013981.","journal-title":"Support Care Cancer"},{"key":"BFpcan201669_CR87","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Newton RU . Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010; 28: 340\u2013347.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40279-014-0269-4","volume":"45","author":"D Finger","year":"2014","unstructured":"Finger D, Goltz FR, Umpierre D, Meyer E, Rosa LHT, Schneider CD . Effects of protein supplementation in older adults undergoing resistance training: a systematic review and meta-analysis. Sports Med 2014; 45: 245\u2013255.","journal-title":"Sports Med"},{"key":"BFpcan201669_CR89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MCO.0b013e32831cef8b","volume":"12","author":"D Paddon-Jones","year":"2009","unstructured":"Paddon-Jones D, Rasmussen B . Dietary protein recommendations and the prevention of sarcopenia: protein, amino acid metabolism and therapy. Curr Opin Clin Nutr Metab Care 2009; 12: 86\u201390.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"BFpcan201669_CR90","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/MCO.0b013e32834b89da","volume":"14","author":"S Graf","year":"2011","unstructured":"Graf S, Egert S, Heer M . Effects of whey protein supplements on metabolism: evidence from human intervention studies. Curr Opin Clin Nutr Metab Care 2011; 14: 569\u2013580.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"BFpcan201669_CR91","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40279-016-0504-2","volume":"46","author":"TA Churchward-Venne","year":"2016","unstructured":"Churchward-Venne TA, Holwerda AM, Phillips SM, van Loon LJC . What is the optimal amount of protein to support post-exercise skeletal muscle reconditioning in the older adult? Sports Med 2016; 46: 1205\u20131212.","journal-title":"Sports Med"},{"key":"BFpcan201669_CR92","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3945\/ajcn.2010.29649","volume":"93","author":"B Pennings","year":"2011","unstructured":"Pennings B, Koopman R, Beelen M, Senden JM, Saris WH, van Loon LJ . Exercising before protein intake allows for greater use of dietary protein\u2013derived amino acids for de novo muscle protein synthesis in both young and elderly men. Am J Clin Nutr 2011; 93: 322\u2013331.","journal-title":"Am J Clin Nutr"},{"key":"BFpcan201669_CR93","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3945\/ajcn.113.064154","volume":"99","author":"RM Daly","year":"2014","unstructured":"Daly RM, O'Connell SL, Mundell NL, Grimes CA, Dunstan DW, Nowson CA . Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlledtrial. Am J Clin Nutr 2014; 99: 899\u2013910.","journal-title":"Am J Clin Nutr"},{"key":"BFpcan201669_CR94","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/gerona\/gls221","volume":"68","author":"A Chale","year":"2013","unstructured":"Chale A, Cloutier GJ, Hau C, Phillips EM, Dallal GE, Fielding RA . Efficacy of whey protein supplementation on resistance exercise-induced changes in lean mass, muscle strength, and physical function in mobility-limited older adults. J Gerontol A Biol Sci Med Sci 2013; 68: 682\u2013690.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BFpcan201669_CR95","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2007.15.4963","volume":"27","author":"RJ Segal","year":"2009","unstructured":"Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27: 344\u2013351.","journal-title":"J Clin Oncol"},{"key":"BFpcan201669_CR96","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1188\/15.ONF.348-356","volume":"42","author":"KM Winters-Stone","year":"2015","unstructured":"Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM . Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer. Oncol Nurs Forum 2015; 42: 348\u2013356.","journal-title":"Oncol Nurs Forum"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pcan201669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201669","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pcan.2016.69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:03:19Z","timestamp":1684472599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFpcan201669"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.69","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"5 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}